The Genome Analysis Shared Resource (GEN) provides Mayo Clinic Cancer Center (MCCC) members efficient, high-quality, cost-effective access to state-of-the-art genomics technologies for studying gene structure and function. Since 2003, the GEN components have been working in a coordinated fashion to provide technical expertise, instrumentation, and comprehensive support for nucleic acid sequencing, gene expression profiling, and genotyping. Support for NextGen sequencing and gene expression regulation through RNAi analysis were added in 2007. The services provided by the facility include deep sequencing studies of RNA and DNA on Illumina NovaSeq, HiSeq and MiSeq instruments, and Pacific Biosciences Single Molecule Real Time Sequencing on the new Sequel platform. In addition, we offer full-service genotyping and gene transcript analysis using Affymetrix Genechip? technology and Illumina BeadChips. Methylation analyses are offered using Illumina methylation arrays and reduced representational bisulfite sequencing on Illumina HiSeq instruments. An important additional capability is offered by the RNA Interference shared resource, which provides special contract pricing on packaging reagents for lentiviral production and access to the complete Open Biosystems pGIPZ knockdown library to all Mayo Clinic investigators. Each of the 4 areas of focus (Sequencing, Gene Expression, Genotyping and RNA Interference) is directed by a senior staff-level Associate Director with expertise in the area of focus. With significant institutional support, we have continued to add new instruments, personnel and services in support of MCCC activities. There is a well-developed cooperative administrative structure that oversees our activities and ensures timely access and affordable pricing to MCCC members. All of our activities are data intensive, and we interact closely with the IT and bioinformatics resources to meet the needs of our users, from project inception through the final delivery of data. Since the last competitive grant renewal, more than 158 MCCC members from the 10 Programs and all 3 MCCC sites have used the services offered by the GEN and MCCC projects account for about half of all the activity in the GEN. The value of this resource to the MCCC is highlighted by the large number of high-quality, peer-reviewed publications that were based upon data produced in our facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113593
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications